Asset Details
Do you wish to reserve the book?
Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab
Do you wish to request the book?
Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab
2018
Overview
EGFR-antibodies are associated with significant skin toxicity, including acneiform rash and folliculitis. It remains impossible to predict the occurrence of severe skin toxicity due to the lack of predictive markers. Here, we present the first genome-wide association study (GWAS) to find single nucleotide polymorphisms (SNPs) associated with EGFR inhibitor-induced skin toxicity using data of the multicentre randomized phase III CAIRO2 trial (clinicaltrials.gov NCT00208546). In this study, advanced or metastatic colorectal cancer patients were treated with capecitabine, oxaliplatin and bevacizumab with or without cetuximab. Germline DNA was available in 282 of the 368 patients in the cetuximab arm. Mild skin toxicity occurred in 195 patients (i.e. CTC grade 1 or 2, respectively 91 and 104 patients) and severe skin toxicity (i.e. grade 3) in 36 patients. Grade 4 skin toxicity did not occur. None of the SNPs reached the formal genome wide threshold for significance of 5x10(-8), though SNPs of at least 8 loci did show moderate association (p-value between 5x10(-7) and 5x10(-5)) with the occurrence of grade 3 (severe) skin toxicity. These SNPs did not overlap with SNPs associated with cetuximab efficacy as found in a previous GWAS in the same CAIRO2 cohort. If formally proven by replication, the SNPs associated with severe EGFR induced skin toxicity may be helpful to predict the occurrence and severity of skin toxicity in patients that will receive cetuximab and allow for adequate information on the risk of skin toxicity and prophylactic measurements.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Aged
/ Analysis
/ Antineoplastic Agents, Immunological - adverse effects
/ Cancer
/ Clinical Trials, Phase III as Topic
/ Colorectal Neoplasms - drug therapy
/ DNA
/ Drug Eruptions - prevention & control
/ Epidermal growth factor receptors
/ Female
/ Genetic Predisposition to Disease
/ Genome-wide association studies
/ Genome-Wide Association Study
/ Genomes
/ Humans
/ Male
/ Medicine and Health Sciences
/ Mutation
/ Oncology
/ Patients
/ Pharmacy
/ Polymorphism, Single Nucleotide
/ Randomized Controlled Trials as Topic
/ Single-nucleotide polymorphism
/ Skin
/ Studies
/ Toxicity
